Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)Simona Di Giambenedetto, Gabriella d’Ettorre, Andrea Antinori et al.|Journal of Antimicrobial Chemotherapy|2016Cited by 75
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical TrialStefano Rusconi, Giulia Marchetti, Paola Vitiello et al.|PLoS ONE|2013Cited by 42
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trialMassimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli et al.|Journal of Antimicrobial Chemotherapy|2018Cited by 33